Previous 10 | Next 10 |
home / stock / ckpt / ckpt articles
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in th...
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics,...
ATLANTA, April 08, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint...
WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy an...
The Nasdaq 100 closed higher by around 300 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell share...
WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and...
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and...
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Checkpoint Therapeutics, Inc. ("Chec...
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of Checkpoint Therapeutics, Inc. ("Checkpoint" or t...
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...